(Q33538428)

27 July 2017

1 reference

title

HER-2/neu as a predictive marker of response to breast cancer therapy (English)

1 reference

27 July 2017

1 reference

M D Pegram

1

1 reference

27 July 2017

G Pauletti

series ordinal

2

1 reference

27 July 2017

D J Slamon

series ordinal

3

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 January 1998

1 reference

Breast Cancer Research and Treatment

27 July 2017

published in

1 reference

27 July 2017

volume

52

1 reference

27 July 2017

issue

1-3

1 reference

27 July 2017

page(s)

65-77

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

c-erbB-2 oncoprotein expression in primary and advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

Advances in DNA diagnostics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

7 January 2021

neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

7 January 2021

The HER-2/neu oncogene in breast cancer: so what is new?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

7 January 2021

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

7 January 2021

Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

7 January 2021

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

7 January 2021

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

7 January 2021

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

7 January 2021

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006111117877

7 January 2021

Identifiers

DOI

10.1023/A:1006111117877

1 reference

Dimensions Publication ID

27 July 2017

1037590396

0 references

1 reference